Oslo University Hospital HF
- Address
- Klaus Torgardsvei 3, 0371 Oslo, Norway
Oslo University Hospital HF - Diabetes and Cellular Therapy Research
Oslo University Hospital HF is engaged in cutting-edge research focused on innovative cellular therapies for complex metabolic disorders. The center participates in advanced clinical trials exploring novel treatment approaches for patients with diabetes and related complications, particularly those experiencing severe and life-threatening manifestations of the disease.
- Type 1 Diabetes Mellitus with severe complications
- Impaired hypoglycemic awareness and severe hypoglycemia management
- Cell-based regenerative therapies (VX-880) for metabolic diseases
The hospital's research portfolio emphasizes addressing impaired hypoglycemic awareness, a critical complication where patients lose the ability to recognize dangerous drops in blood sugar. Through participation in multi-phase clinical trials, Oslo University Hospital HF contributes to evaluating the safety, tolerability, and efficacy of novel cell infusion therapies designed to restore normal glucose regulation and potentially transform outcomes for patients with Type 1 Diabetes Mellitus who face severe hypoglycemic episodes despite conventional management strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Vertex Pharmaceuticals Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oslo University Hospital HF
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of the Safety, Tolerability, and Efficacy of Zimislecel (VX-880) in Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia | Vertex Pharmaceuticals Inc. | Phase IV | Recruiting | May 2023 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| ZIMISLECEL | 1 | Unknown | 2023-05-26 | 2023-05-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.